Can Parathyroid Hormone Injections Reverse Glucocorticoid-induced Osteoporosis
Osteoporosis
About this trial
This is an interventional treatment trial for Osteoporosis focused on measuring Parathyroid hormone (1-34), Glucocorticoid-induced osteoporosis, Postmenopausal women, osteoporotic fractures
Eligibility Criteria
Inclusion Criteria: Postmenopausal women on glucocorticoids (prednisone 5mg/d or greater Osteopenia by T score of hip or lumbar spine of -2.0 All study subjects must be on a stable dose of estrogen/progesterone or raloxifene Ambulatory and able to come to the clinical center 9 times over 2 years Willing to sign an informed consent Exclusion Criteria: Generalized disease of the bone (other than glucocorticoid-induced osteoporosis), including hyperparathyroidism, hyperthyroidism, Paget's disease) Diseases that affect bone metabolism (e.g. alcoholism, inflammatory bowel disease, malabsorption, renal disease (Cr2) or liver disease (transaminase level 2 times limit of normal) Within the past 1 year, regular use of medications that are known to affect bone metabolism (e.g. anabolic steroids, anticoagulants, anticonvulsants, pharmacologic doses of vitamin D and vitamin A supplements). History of drug abuse Senile dementia, paraplegia and/or quadriplegia Unstable rheumatic disease with clinically significant renal or central nervous system involvement.
Sites / Locations
- San Francisco General Hospital